Fake And Substandard Drugs Entering Legitimate US Supply Chain, Authorities Warn
A preliminary report warns of potentially serious threats to the legitimate US drug supply chain of counterfeit and substandard drugs, say the FDA (Food and Drug Administration), NABP (National Association of Boards of Pharmacy) and some pharmaceutical companies. The FDA warns of serious risks and vulnerabilities in the drug supply chain in the USA. The FDA wrote yesterday: "Review revealed ...

Landmark NORD Study Concludes FDA Is Flexible In Reviewing Therapies For Rare Diseases
The National Organization for Rare Disorders (NORD) today released a landmark report documenting flexibility in the Food and Drug Administration (FDA) review of potential treatments for patients with rare diseases.